Avient Launches New Bio-Based Polymer Solutions for Medical and Pharmaceutical Applications During Pharmapack Europe 2022

May 18, 2022

Avient Corporation today announced the expansion of its bio-based polymer solutions for medical and pharmaceutical applications

To download a high-resolution image, please click here: FOR MEDIA USE ONLY
 

PARIS – May 18, 2022 – Avient Corporation, a premier provider of specialized and sustainable material solutions and services, today announced expansion of its line of bio-based Mevopur™ medical-grade polymer solutions. The new color and additive concentrates and tailored ready-to-use formulations are made with bio-based polycarbonate, ABS, or styrenic polymers. These are in addition to bio-based polyolefin materials that Avient introduced in 2021.

These more sustainable additions to the Mevopur portfolio are being featured at Pharmapack Europe 2022, being held 18 and 19 May in the Paris Expo Porte de Versailles. Avient is exhibiting on stand D66.

“Using the new bio-based Mevopur polymer solutions instead of conventional materials,” says Volker Dickfeld, senior marketing manager, healthcare global, “can help manufacturers of pharmaceutical packaging, medical devices and related products reduce their carbon footprint. And, because they are produced under Mevopur protocols, these polymer solutions also can help the manufacturers reduce their risk of regulatory non-compliance.”

Manufactured using non-fossil feedstocks, the new Mevopur concentrates include polymers with bio-based content between 70 and 100%, as calculated to ASTM D6866 standard. Along with pre-colored formulations for users who prefer ready-to-use solutions, they are more sustainable drop-in replacements for fossil-based materials. These bio-based materials can be processed on standard injection-molding machines and extruders and can be recycled in the same recycling channels as conventional fossil-based polymers.

Like other Mevopur formulations, they are produced in dedicated facilities according to ISO 13485-2016 protocols and supported by testing to ISO 10993-1, USP, European Pharmacopeia and ICH Q3D guidelines. Documented change control beyond CAS number is practiced and Registered Drug Master File (DMF) / Device Master File (MAF) documentation is maintained. 

About Avient

Avient Corporation (NYSE: AVNT), with 2021 revenues of $4.8 billion, provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world. Examples include:

• Unique technologies that improve the recyclability of products and enable recycled content to be incorporated, thus advancing a more circular economy
• Light-weighting solutions that replace heavier traditional materials like metal, glass and wood, which can improve fuel efficiency in all modes of transportation and reduce carbon footprint
• Sustainable infrastructure solutions that increase energy efficiency, renewable energy, natural resource conservation and fiber optic / 5G network accessibility

Avient employs approximately 8,700 associates and is certified ACC Responsible Care®, a founding member of the Alliance to End Plastic Waste and certified Great Place to Work®. For more information, visit www.avient.com.

To access Avient’s news library online, please visit www.avient.com/news.

# # #

Media contact: 
Scott Collins 
scollins@collins-marcom.com 
+1 216.382.8840